CSF3 and non-Hodgkin lymphoma: Our literature search identified 4 additional RCTs of pegfilgrastim vs. no primary G-CSF, which were conducted in populations with colorectal cancer, [24] breast cancer, [23] non-Hodgkin's lymphoma, [22] and various solid tumours; [22] the latter three studies were restricted to elderly patients.